The premature termination of the torcetrapib trial in December 2006 was widely publicized. A year on, Anatol Kontush, Maryse Guérin and M John Chapman revisit cholesteryl ester transfer protein inhibition as a potential therapeutic target and review recent developments in HDL-raising therapy with a focus on torcetrapib trials.
- Anatol Kontush
- Maryse Guérin
- M John Chapman
